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Abstract: Despite ongoing therapeutic innovations, metastatic breast cancer (MBC) remains a 
treatable but incurable disease. In the developed world, a diagnosis of MBC without a preceding 
diagnosis of early stage disease is a rare event. However, approximately one-third of women 
with early stage breast cancer ultimately experience a distant recurrence. Because the majority 
of breast cancers express estrogen and/or progesterone receptors and are accordingly considered 
hormone-sensitive, therapeutic strategies that interfere with hormone-mediated tumorigenesis 
have been a cornerstone of the breast cancer management paradigm for decades. Historically, 
the selective estrogen receptor modulator tamoxifen has been the most extensively studied and 
widely used hormone maneuver in breast cancer. However, a recent therapeutic innovation, 
namely the successful development of third-generation aromatase inhibitors (AIs), has had a 
dramatic impact on the treatment paradigm for women with hormone-sensitive MBC. Because 
of the demonstrated efficacy in postmenopausal breast cancer patients, the generally favorable 
side-effect profile, and the convenience of oral administration, AIs are now in widespread 
clinical use. Currently, there are three clinically available third-generation AIs: two reversible, 
nonsteroidal AIs, letrozole and anastrozole; and one irreversible, steroidal AI, exemestane. All 
three agents are at least as efficacious as tamoxifen as monotherapy for postmenopausal women 
with hormone-sensitive MBC. Current clinical research aims to improve upon existing strategies 
by evaluating AIs in combination with systemic chemotherapy regimens and/or novel targeted 
agents. It is hoped that these therapeutic innovations will lead to ongoing improvements in 
quality of life parameters and ideally survival for women with hormone-sensitive MBC.
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Introduction
Breast cancer is a global public health burden with more than one million new cases 
diagnosed annually.1 Worldwide, the distribution of early versus advanced cases 
varies widely. In the developed world, for example, a diagnosis of metastatic breast 
cancer (MBC) without a preceding diagnosis of early stage disease is a rare event.1,2 
However, despite ongoing therapeutic innovations, approximately one-third of women 
with an early stage diagnosis ultimately develop metastatic disease. Once distant 
metastases occur, breast cancer is treatable but no longer curable and is associated 
with a median survival of only two to three years.2 Consequently, investigators strive, 
through therapeutic innovation, to improve quality-of-life outcomes by preventing or 
relieving cancer-related symptoms and, ideally, to optimize disease-specific outcomes 
including disease free and overall survival. Typically, MBC management strategies are 
devised after considering a number of patient and tumor characteristics including the International Journal of Women’s Health 2009:1 68
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disease-free interval, the prior adjuvant therapy prescription, 
the number of metastatic sites, the potential for visceral 
crisis, patient age, patient preference, co-morbid condi-
tions, performance status, and tumor biomarkers including 
human epidermal growth factor receptor 2 (HER2) status and 
hormone receptor status. Treatment strategies are increas-
ingly tailored to the biology of an individual’s tumor and 
information about hormone receptor status, one of the earliest 
known breast cancer biomarkers, remains critical.
The majority of breast cancers in the developed world 
are considered “hormone-sensitive.” Although significant 
controversy persists regarding the optimal definition of 
“hormone-sensitive,” hormone receptor status is typically 
defined by immunohistochemistry (IHC) determined estrogen 
receptor (ER) and/or progesterone receptor (PR) expression 
and reported as a percentage of cells staining positive or 
as the intensity of staining.3 Although no consensus exists 
regarding a specific cut-off to define hormone sensitivity, 
hormone therapies are typically preferred over systemic 
chemotherapy strategies in the initial treatment of most 
women with hormone-sensitive MBC who are not at risk 
for visceral crisis. The typical advantages of hormone-
targeted strategies include the demonstrated efficacy, the 
generally favorable side-effect profile, and the general 
ease of administration. Additional features of potentially 
appropriate candidates for endocrine therapy include a long 
disease-free interval between primary breast cancer diagnosis 
and the development of metastases, minimal MBC-related 
symptoms, and modest disease burden.
For decades, the hormone treatment strategy was largely 
dominated by the selective estrogen receptor modulator, 
tamoxifen. Tamoxifen is a complicated and incompletely 
understood drug with beneficial anti-estrogen effects in 
breast tissue and deleterious pro-estrogen effects elsewhere, 
ultimately accounting for the small but significantly increased 
risk of venous thromboembolic events and uterine cancers 
observed with its administration.4 However, the tamoxifen-
based treatment strategies were ultimately revised with the 
development of a novel class of hormone-targeting agents 
(AIs). The first generation of AIs demonstrated promising 
activity in the early clinical studies but had the significant 
disadvantage of requiring parenteral administration to optimize 
activity.5–7 Numerous refinements to the chemical structure 
ensued, and the currently available, orally-administered, 
third-generation AIs are highly active and generally well 
tolerated. The most commonly cited AI-mediated side-effects 
include myalgias and arthralgias that typically affect the 
small joints of the hands, and menopausal-like symptoms 
including hot flashes.8 Although AI administration is also 
associated with a significant rate of bone mineral density 
declines in the adjuvant setting,8 this potential side-effect 
is of lesser relevance in the metastatic setting given that 
hormone-sensitive MBC frequently involves bone and the 
majority of these patients are treated with bisphosphonates.
Menopausal status is a critical determinant of patient 
selection for AI therapy. In premenopausal women 
the primary source of estrogen is the ovaries, while in 
postmenopausal women estrogen is produced mainly from 
androgen precursors in adipose tissue. A critical step in the 
peripheral conversion of androgen precursors to estrogen is 
catalyzed by aromatase, an enzyme that is reversibly inhibited 
by the nonsteroidal AIs, letrozole (Femara®; Novartis, Basel, 
Switzerland) and anastrozole (Arimidex®; AstraZeneca, 
Wilmington, DE, USA), and irreversibly by the steroidal 
AI exemestane (Aromasin®; Pfizer, New York, NY, USA). 
Because peripheral inhibition of aromatase cannot overcome 
ovary-derived estrogen production, AI monotherapy is 
not appropriate for premenopausal women with MBC.9,10 
Furthermore, because of the potential for increased gonado-
tropin secretion and thus, ovarian follicular stimulation, it 
may even be deleterious in this setting. Some clinicians 
have adopted a practice of rendering premenopausal patients 
medically or surgically postmenopausal (with GnRH agonists 
or bilateral salpingo-oophorectomy) and then introducing AI 
therapy. However, it is important to note that this approach is 
an extrapolation of the data from the postmenopausal setting 
and has not yet been validated in an adequately powered 
randomized study. Thus, the following discussion is limited 
to the evidence for AI strategies in postmenopausal women 
with hormone-sensitive MBC only.
Strategies for postmenopausal 
women with hormone-sensitive MBC
The three third-generation AIs (letrozole, anastrozole, and 
exemestane) are at least as efficacious as tamoxifen for the 
first-line treatment of postmenopausal women with hormone-
responsive MBC (Table 1).11–17 For example, a combined 
analysis of 1,021 women with advanced breast cancers 
that were either ER-positive, PR-positive or of unknown 
receptor status, participating in two large randomized studies 
of first-line anastrozole versus tamoxifen, was recently 
reported.12,17 In this analysis, at a median follow-up of 
18.2 months, there was no significant difference in objective 
response rate (ORR) between the study arms (27.1% for 
tamoxifen versus 29.0% for anastrozole, p = 0.1129) and 
only a trend in favor of anastrozole for progression-free International Journal of Women’s Health 2009:1 69
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survival (PFS; 7.0 versus 8.5 months, p = 0.103). However, 
in a retrospective subgroup analysis of the 60% of trial 
participants with ER-positive and/or PR-positive tumors, 
anastrozole proved superior to tamoxifen for time to progres-
sion (TTP) (median values of 10.7 months for anastrozole 
and 6.4 months for tamoxifen, p = 0.022). Notably, because 
of the low event rate at the time of the data cut-off, survival 
analyses were not initially performed. However, in an updated 
analysis at a median follow-up of 43.7 months, no significant 
difference in survival was observed (median time to death: 
40.8 and 41.3 months for anastrozole versus tamoxifen, 
respectively; hazard ratio [HR] 0.97, lower 95% confidence 
limit 0.84). Similar results have been observed in first-line 
MBC studies of letrozole or exemestane versus tamoxifen. 
In a multicenter study of 916 patients with hormone receptor-
positive or unknown advanced breast cancer randomized to 
letrozole or tamoxifen, with optional cross-over permitted 
and 32 months of follow-up, letrozole proved superior to 
tamoxifen for TTP (9.4 versus 6.0 months, respectively; 
p  0.0001) and ORR (32% versus 21%, p = 0.0002).14 
A nonsignificant trend toward a survival benefit was observed 
in favor of letrozole (34 versus 30 months, p = 0.53), 
however, the absence of a clear survival benefit may reflect 
the approximately 50% cross-over rate. A comparable study 
of 371 women with hormone receptor-positive or hormone 
receptor-unknown advanced breast cancer randomized to 
first-line exemestane or tamoxifen was recently updated.16 
After a median follow-up period of 29 months, the ORR 
proved superior for exemestane compared with tamoxifen 
(46% versus 31%, respectively; p = 0.005). In addition a trend 
toward a PFS benefit in favor of exemestane was observed 
(9.9 versus 5.8 months; p = 0.121). However, no survival 
benefits were observed in favor of either strategy (37.2 versus 
43.3 months; p = 0.821). Although no statistically significant 
survival benefits have been observed in individual studies of 
AIs versus tamoxifen, a recent meta-analysis demonstrated 
a significant survival advantage with 3rd generation AIs 
compared with tamoxifen or progestin therapy.18 Thus, 
overall, the AIs appeared to be at least as efficacious as 
tamoxifen in the first-line MBC setting, although ultimately, 
no definitive survival advantage has been demonstrated with 
this approach. AIs are commonly favored over tamoxifen 
in the first-line setting for postmenopausal women who are 
AI-naïve or who have relapsed more than one year after 
adjuvant AI administration because of the lower incidence 
of thromboembolic events and incident uterine cancers. 
To date, there has been no large, head-to-head comparison 
of all three currently available AIs in this setting, and cross-
trial comparisons should be discouraged. Thus, there is no 
compelling evidence to date indicating superiority of one AI 
over another. Furthermore, it is anticipated that the first-line 
AI MBC strategy will become less relevant as more women 
receive immediate or delayed AIs in the adjuvant setting, and 
thus, might no longer be candidates for upfront AI therapy.
AIs as second-line therapy  
for the treatment of hormone-
sensitive MBC
Although there is currently no evidence to suggest superiority 
of one AI over another in the first-line MBC setting, clinical 
strategies have recently been shaped by the reporting of a 
large study evaluating second-line hormone strategies in this 
setting. In the Evaluation of Faslodex versus Exemestane 
Clinical Trial (EFECT) study, 693 postmenopausal women 
with hormone receptor-positive advanced breast cancer with 
disease progression or recurrence on a nonsteroidal AI were 
randomly assigned to receive either intramuscular fulvestrant, 
a pure antiestrogen, or oral exemestane.19 The study was both 
double-blinded and placebo controlled. In the analysis, no 
significant difference was observed between the two study 
arms for the primary endpoint of TTP (3.7 months in each 
Table 1 Selected studies of first-line tamoxifen versus an aromatase inhibitor in metastatic breast cancer
   Tamoxifen versus 
Anastrozole12,17,39
Tamoxifen versus 
Letrozole14
Tamoxifen versus 
Exemestane16
Patients 1021 er+, Pr+ or Hr-unknown 916 Hr+/unknown 371 Hr+/unknown
Median follow-up (months) 43.7 32 29
Orr (%) 27 vs 29 (P = 0.1129) 21 vs 32 (P = 0.0002) 31 vs 46 (P = 0.005)
TTP/PFS (months) TTP 7.0 vs 8.5 (P = 0.103) TTP 6.0 vs 9.4 (P  0.0001) PFS 5.8 vs 9.9 (P = 0.121)
MS (months) 40.1 vs 39.2 (Hr = 0.97, lower 
95% CL = 0.84)
30 vs 34 (P = 0.53) 37.2 vs 43.3 (P = 0.821)
Abbreviations: er, estrogen receptor; Pr, progesterone receptor; Hr, hormone receptor; Orr, objective response rate; TTP, time to progression; PFS, progression free 
survival; MS, median survival; CL, Confidence Limit.International Journal of Women’s Health 2009:1 70
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arm; p = 0.6531). Furthermore, no significant difference was 
observed between the study arms for ORR (7.4% versus 6.7% 
for fulvestrant versus exemestane, respectively; p = 0.736). 
Although the reported ORR was modest, it should be noted 
that a significant group of patients had stable disease such 
that the clinical benefit rate (CBR, the combined rate of 
objective responses and stable disease) was 32.2% and 
31.5% in the fulvestrant and exemestane groups, respectively. 
Thus, CBR may be a more relevant end-point than TTP for 
patients with hormone-sensitive MBC, given that many have 
bone-dominant disease which can be difficult to measure 
by standard response evaluation criteria. In summary, the 
EFECT study not only confirmed that a subset of patients 
with hormone-sensitive MBC can derive durable benefits 
from serial endocrine manipulation but also indicated that 
some patients with tumor progression on a nonsteroidal AI 
can derive benefit from a switch to a steroidal AI and that 
the benefits are equivalent to those observed with a different 
class of intramuscularly-administered hormone therapies. 
As a result, the arsenal of orally available, active agents with 
favorable toxicity profiles was broadened for women with 
hormone-sensitive MBC.
Other studies of AIs for the treatment 
of hormone-sensitive MBC
AIs have been evaluated against other conventional hormone 
maneuvers for postmenopausal women with hormone-
sensitive MBC. For example, equivalent efficacy was demon-
strated in two phase III trials of anastrozole versus fulvestrant 
in women with primarily tamoxifen-resistant MBC.20,21 
Furthermore, all three AIs have been evaluated against 
megestrol acetate (Megace) in women with tamoxifen-
resistant MBC with consistent survival benefits in favor of the 
AI.22–24 Given the number of efficacious hormone maneuvers 
for hormone-sensitive MBC, no single treatment paradigm 
exists. However for appropriately selected postmenopausal 
women, many clinicians now opt for a nonsteroidal AI in the 
first-line MBC setting followed by a steroidal AI with disease 
progression as per the EFECT study design. Depending on 
a number of patient and tumor characteristics including the 
pace of an individual’s disease and the prior therapy history, 
other hormone maneuvers including tamoxifen, fulvestrant, 
or megestrol acetate may subsequently be considered and 
cytotoxic therapy delayed if possible.
AI-based combination strategies
Given the efficacy demonstrated with AI monotherapy in 
MBC, clinical investigators have endeavored to derive further 
improvements by combining AIs with various conventional 
chemotherapy and novel targeted strategies. In a retrospec-
tive systematic review of various chemotherapy, hormone 
therapy and combination strategies among 31,510 patients 
with MBC participating in 189 clinical trials, no survival 
benefit was observed with chemotherapy combined with 
hormone therapy versus chemotherapy alone in the relevant 
subset of 3,606 patients.25 Consequently, combination 
chemotherapy-AI strategies are not typically recommended 
in clinical practice off-study. However, combination strate-
gies with other targeted agents, including HER2-directed and 
antiangiogenesis molecules are ongoing.
In both the adjuvant and metastatic setting, significant 
benefits have been observed with HER2-targeted therapies 
among the 20%–30% of patients with HER2-“positive” breast 
cancer, where HER2 status is determined by assessment of gene 
amplification and/or protein overexpression.26–30 Approximately 
50% of HER2-positive breast cancers are hormone-sensitive 
and preclinical models implicate cross-talk between ER and 
HER2 as a putative mechanism of endocrine-resistance.31 
Consequently, there has been considerable interest in studies 
evaluating hormone- and HER2-targeted combination therapies. 
In a phase II study of first or second-line letrozole in combina-
tion with a HER2-directed humanized monoclonal antibody, 
trastuzumab (Herceptin®; Genentech, San Francisco, CA, 
USA), in 33 women with hormone-sensitive, HER2-positive 
advanced breast cancer, an ORR of 26% and a CBR of 52% 
were observed.32 In the phase III TAnDEM study, 207 patients 
with hormone-sensitive, HER2-positive MBC were randomized 
to first-line anastrozole alone or in combination with 
trastuzumab.33 The combination was associated with a signifi-
cant improvement in PFS (4.8 versus 2.4 months; p = 0.0016) 
and a trend toward an overall survival benefit that was not 
statistically significant (28.5 versus 23.9 months; p = 0.325). 
Preliminary results from another phase III study of combina-
tion endocrine- and HER2-targeted therapy were also recently 
reported. In EGF30008, 1286 postmenopausal women with 
hormone receptor-positive MBC were randomized to letrozole 
with or without lapatinib, an oral tyrosine kinase inhibitor 
of both HER1 and HER2.34 Notably, only 219 (17%) of 
enrolled patients had HER2-positive breast cancer. Among the 
patients with HER2-positive MBC, combination therapy was 
associated with significant improvements in PFS (3.0 versus 
8.2 months; p = 0.019) and ORR (15% versus 28%; p = 0021) 
but no significant survival benefit (32.3 versus 33.3 months for 
letrozole alone or the combination, respectively; p = 0.113). 
Not surprisingly, there were no PFS (13.4 versus 13.7 months; 
p = 0.188) or ORR (32 versus 33%; p = 0.726) benefits observed International Journal of Women’s Health 2009:1 71
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with the addition of lapatinib in the HER2-normal population. 
However, overall, the addition of lapatinib to letrozole was 
associated with an increased incidence of clinically relevant 
adverse events, including a 10% increase in the rate of grade 3/4 
diarrhea. Therefore, both studies demonstrated improved 
outcomes with combined AI and HER2-targeted strategies in 
appropriately selected populations. However, because neither 
study design included an anti-HER2 monotherapy arm, it is 
unknown whether a combined approach is superior to HER2-
targeted therapy alone. Thus, because first-line AI monotherapy 
has the convenience of oral administration and a generally 
well tolerated side-effect profile, clinicians frequently delay 
introducing HER2-targeted strategies until hormone strategies 
have been exhausted or are no longer appropriate.
Angiogenesis plays a critical role in physiologic growth 
as well as tumor growth and metastasis. Bevacizumab is 
a humanized monoclonal antibody against an angiogenic 
factor, vascular endothelial growth factor (VEGF), and 
has been shown to improve PFS when combined with 
taxane-containing regimens in MBC.35 Because estrogen 
modulates VEGF-induced angiogenesis in hormone-sensitive 
MBC, AI and bevacizumab combination strategies are being 
investigated. For example, in a phase II study of letrozole 
with bevacizumab, the combination was well-tolerated 
with preliminary evidence of activity.36 Phase III studies 
examining this approach are ongoing.
Another putative mechanism of endocrine-resistance 
in MBC is increased expression of the epidermal growth 
factor receptor (EGFR). Preclinical models indicated 
that endocrine resistance could be overcome with EGFR 
targeted agents such as gefitinib, an oral tyrosine kinase 
inhibitor of EGFR. However, in clinical breast cancer mod-
els, gefitinib in combination with endocrine therapy has 
demonstrated variable activity. For example, in a recently 
reported randomized phase II study, the addition of gefitinib 
to anastrozole was associated with marked improvements 
in PFS (8.2 versus 14.5 months; HR 0.55, 95% confidence 
interval [CI]: 0.32–0.94) in women with hormone-sensitive 
MBC.37 However, in a randomized, phase II study of 
216 postmenopausal women, the addition of neoadjuvant 
gefitinib to anastrozole failed to improve response rate or to 
decrease cell proliferation index.38 Further studies are needed 
to determine whether this is indeed a valid approach.
Conclusion
Hormone therapies remain a therapeutic cornerstone for 
patients with hormone receptor-positive MBC, modest 
disease burden and low risk of visceral crisis. Aromatase 
inhibitors represent an important therapeutic innovation 
in the management of hormone receptor-positive MBC, 
demonstrating superior benefits compared with conventional 
hormone maneuvers such as megestrol acetate and efficacy 
profiles at least equivalent and potentially superior to 
tamoxifen in the first-line MBC setting. The oral route of 
administration and generally tolerable side-effect profile 
add to their clinical appeal. It is anticipated, however, 
that as more women receive an adjuvant AI prescription, 
that the MBC treatment algorithm will need to be revised 
accordingly. It is also hoped that novel strategies whereby 
AIs are administered in combination with other treatments 
including novel cytotoxics and biologic agents, will confer 
additional survival benefits in this population.
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